AJMC August 15, 2024
Pharmacy benefit managers (PBMs), the so-called drug middlemen that were created with the mission of reining in costs, appear to have had the opposite effect for the American consumer—driving up drug costs, pushing independent pharmacies into oblivion, and creating incentives that crush low-cost options such as generics and biosimilars, according to a scathing report issued July 9, 2024, by the Federal Trade Commission (FTC).1
If Congress takes action against PBMs later this year, July 2024 will mark the month when things got serious. This follows a multiyear effort by community oncology practices to highlight how PBMs are undermining physician choices and, in some cases, punishing doctors for protecting patients. In a few weeks’ time, years of work at the agency,...
Today's Sponsors
Today's Sponsor